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Objective: Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its
relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely
understood. RBD and cholinergic system degeneration are identified independently as risk factors for cognitive
impairment in PD. We aimed to assess the association between cholinergic denervation and symptoms of RBD in PD
patients without dementia.
Methods: Eighty subjects with PD without dementia (age, 64.6 6 7.0 years; range, 50–82 years; 60 males,
20 females; mean Montreal Cognitive Assessment Test [MoCA] score, 26.2 6 2.1; range 21–30) underwent
clinical assessment, neuropsychological testing, and [11C]methylpiperidyl propionate acetylcholinesterase and
[11C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission tomography (PET)
imaging. 11C3-Amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) serotonin transporter PET
imaging was performed in a subset of 35 subjects. The presence of RBD symptoms was determined using the Mayo
Sleep Questionnaire.
Results: Twenty-seven of 80 subjects (33.8%) indicated a history of RBD symptoms. Subjects with and without RBD
symptoms showed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease
Rating Scale motor scores, or striatal DTBZ binding. Subjects with RBD symptoms, in comparison to those without,
exhibited decreased neocortical, limbic cortical, and thalamic cholinergic innervation (0.0213 6 0.0018 vs 0.0236 6
0.0022, t ¼ 4.55, p < 0.0001; 0.0388 6 0.0029 vs 0.0423 6 0.0058, t ¼ 2.85, p ¼ 0.0056; 0.0388 6 0.0025 vs 0.0427
6 0.0042, t ¼ 4.49, p < 0.0001, respectively). Brainstem and striatal DASB binding showed no significant differences
between groups.
Interpretation: The presence of RBD symptoms in PD is associated with relative neocortical, limbic cortical, and
thalamic cholinergic denervation although not with differential serotoninergic or nigrostriatal dopaminergic
denervation. The presence of RBD symptoms may signal cholinergic system degeneration.
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Rapid eye movement (REM) sleep behavior disorder(RBD) is characterized by loss of normal atonia and
oneiric behavior, including abnormal and sometimes vio-
lent motor manifestations, during REM sleep.1 RBD is a
common nonmotor comorbidity of Parkinson disease
(PD) and may be associated with increased risk of cogni-
tive impairment.2,3 PD is a multisystem neurodegenera-
tive syndrome, and cognitive impairment in PD is likely
the result of neurodegeneration within several brain sys-
tems associated with multiple neurotransmitter deficien-
cies.4,5 Striatal dopaminergic denervation probably con-
tributes to cognitive impairments in PD, but deficits of
other neurotransmitter systems, notably cholinergic path-
ways, are also important. In contrast to middle stage
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(Braak 3 and 4) PD, where there is uniform and severe
striatal dopaminergic denervation,6 convergent evidence
from in vivo imaging and postmortem studies indicates
that the magnitude of forebrain cholinergic deficits
increases over the course of PD disease progression and
correlates significantly with the presence of cognitive
impairment in PD.5,7–10 Hilker et al, for example, did
not observe differences in striatal fluorodopa uptake
reductions between PD and PD with dementia (PDD)
groups, but the PDD group had significantly reduced
neocortical acetylcholinesterase (AChE) activity compared
to PD subjects.9 Cholinergic system deficits appear to
advance in parallel with the progression of cognitive
impairments.5,7–10
As both RBD and cholinergic denervation are risk
factors for cognitive impairment in PD, we aimed to inves-
tigate the potential association between RBD symptoms
and cholinergic system integrity in neocortical, thalamic,
and limbic cortical regions of PD subjects. We compared
cholinergic system changes with the degree of nigrostriatal
dopaminergic denervation in the same subjects.
Another important subcortical system that may be
involved in the pathogenesis of RBD is the brainstem seroto-
ninergic system. Rostral brainstem serotonergic nuclei inner-
vate cortical and subcortical structures, including the striatum,
via projections arising from the raphe complex. Serotoninergic
raphe projections within the brainstem may also regulate the
normal function of circuits involved in the pathophysiology
of RBD.11 Serotoninergic raphe complex neurons degenerate
in PD, and loss of serotoninergic raphe neurons may be a rel-
atively early event in the course of PD.11,12 For this reason,
we also evaluated serotoninergic raphe nucleus neuron integ-
rity in a subset of subjects studied.
Patients and Methods
Subjects and Clinical Test Battery
This cross-sectional study involved 80 subjects with PD (20
women and 60 men). All subjects met the UK Parkinson Dis-
ease Society Brain Bank Research Center clinical diagnostic cri-
teria for PD.13 Diagnosis of PD was confirmed by the presence
of nigrostriatal dopaminergic denervation on [11C]dihydrotetra-
benazine (DTBZ) positron emission tomography (PET) imag-
ing. Patients had mild to moderate severity of disease: 3 sub-
jects in Hoehn–Yahr (H-Y) stage 1, 5 in H-Y stage 1.5, 20 in
H-Y stage 2, 40 in H-Y stage 2.5, and 12 in H-Y stage 3.14
The mean duration of disease was 6.0 6 3.9 (standard devia-
tion) years, with a range of 1 to 19 years. Subjects with
Montreal Cognitive Assessment (MoCA) scores <20 were
excluded.15 The mean MoCA score was 26.2 6 2.1 (range,
21–30). The Movement Disorder Society-revised Unified Par-
kinson Disease Rating Scale (UPDRS) was performed in the
practically defined off state.16 No patients were using anticholi-
nergic or cholinesterase inhibitor drugs, and no subjects who
underwent 11C3-amino-4-(2-dimethylaminomethyl-phenylsul-
faryl)-benzonitrile (DASB) imaging were using drugs that might
modify serotonergic neurotransmission.
Standard Protocol Approvals, Registrations, and
Patient Consents
The study was approved by the institutional review board of
the University of Michigan. Written informed consent was
obtained from all subjects.
Mayo Sleep Questionnaire
Symptoms of RBD were assessed using the informant-based
response to question #1 on the Mayo Sleep Questionnaire
(MSQ): ‘‘Have you ever seen the patient appear to ‘act out his/
her dreams’ while sleeping?’’17 Affirmative replies were con-
firmed by positive responses to subquestions 1d (‘‘Has the
patients told you about dreams of being chased, attacked, or
that involve defending himself/herself?’’) and 1e (‘‘If the patient
told you about a dream, did the details of the dream match the
movements made while sleeping?’’) of the MSQ administered
to the subject’s bed partner.17 Question #1 of the MSQ was
validated against polysomnography in a multicenter prospective
cohort study of normal elderly subjects and patients with sus-
pected neurodegenerative disease; the sensitivity was 98%, and
specificity was 74%.17
The International Restless Leg Scale (IRLS)18 and the
Parkinson’s Disease Sleep Scale19 were also administered. These
scales have been used in PD subjects to assess for restless legs
syndrome (RLS) and periodic limb movement disorder
(PLMD) of sleep.20,21
Neuropsychological Examination
Early neuropsychological abnormalities in PD are thought to
manifest predominantly with a frontal–subcortical cognitive
syndrome. This includes difficulties with executive functioning,
working memory, attention, set-shifting, and to a lesser extent,
visuospatial difficulties.5 Neuropsychological tests were chosen
to examine these specific cognitive domains following an
approach as reported previously in PD.22 The California Verbal
Learning Test assesses learning/encoding memory difficulties
thought to be a feature of early cognitive impairment in
PD.23,24 Executive function was assessed with the Wechsler
Adult Intelligence Scale III Picture Arrangement, used in PD as
a nontimed test of picture sequencing to make it independent
from motor impairments.25,26 The Delis–Kaplan Executive
Function System sorting and letter verbal fluency subtests27 are
abnormal in PDD, improve with cholinergic therapy,28 and
may reflect severe cholinergic denervation. The Stroop Color
Word Interference test29 and a switching version of the Stroop
3 test in which subjects name the ink, unless the word is sur-
rounded by a box, in which case, they read the word itself
(Stroop 4)30 were both administered. Speed of performance on
Stroop 1 and 2 reflects attentional difficulties29,31; calculating
the difference between Stroop 3 and 4 measures an additional
demand on cognitive flexibility in PD and has been used in
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previous studies by our group.32 Visuospatial function was
assessed using the Benton Judgment of Line Orientation test
used previously in PD.33,34 Composite z scores were calculated
for these different cognitive domains (memory, executive, atten-
tion, and visuospatial functions) based on normative data. Global
cognitive performance was calculated as the average z score for
the 4 cognitive domains. Subjects with evidence of dementia
defined as a global cognitive z score <2 and impaired instru-
mental activities of daily living were not eligible for this study.
Imaging Techniques
DTBZ is a ligand binding to the type 2 vesicular monoamine
transporter (VMAT2) present in monoaminergic presynaptic
terminals. When measured in the striatum, where >95% of
VMAT2 binding sites are associated with dopaminergic termi-
nals,35,36 VMAT2 binding is a useful method for estimating ni-
grostriatal dopaminergic denervation, particularly as its expres-
sion is not thought to be significantly altered by chronic
dopaminergic therapy.37 Methylpiperidynl propionate (PMP)
binds to synaptic AChE, which is recognized as a reliable
marker for brain cholinergic pathways.38,39 PMP undergoes hy-
drolysis to a metabolite retained in brain, and tracer metabolite
retention is a direct function of AChE activity, a surrogate for
the amount of regional AChE and cholinergic terminal integ-
rity. DASB binds selectively to the presynaptic serotonin trans-
porter (SERT) and is recognized as an appropriate surrogate
marker for serotoninergic terminal density.40
DTBZ, PMP, and DASB PET imaging was performed in
3-dimensional (3D) imaging mode using an ECAT HRþ
tomograph (Siemens Molecular Imaging, Knoxville, TN), which
acquires 63 transaxial slices (slice thickness, 2.4mm; intrinsic in-
plane resolution, 4.1mm full-width at half maximum over a
15.2cm axial field of view). A NeuroShield (Scanwell Systems,
Montreal, Canada) head-holder/shielding unit was attached to the
patient’s bed to reduce the contribution of detected photon events
originating from the body outside the scanner field of view.41
Prior to radioligand injections, a 5-minute transmission scan was
acquired using rotating 68Ge rods for attenuation correction of
emission data using the standard vendor-supplied segmentation
and reprojection routines. All subjects were studied supine, with
eyes and ears unoccluded, resting quietly in a dimly lit room.
DTBZ PET Imaging
No-carrier-added (þ)-[11C]DTBZ (250–1,000Ci/mmol at the
time of injection) was prepared as reported previously.42
Dynamic PET scanning was performed for 60 minutes immedi-
ately following a bolus injection of 55% 555MBq (15mCi) (þ)-
[11C]DTBZ (containing <50lg of cold DTBZ mass) over the
first 15 to 30 seconds of the study, whereas the remaining 45%
of the dose was continuously infused over the next 60 minutes,
resulting in stable arterial tracer levels and equilibrium with brain
tracer levels after 30 minutes.43 A series of 15 scan frames over
60 minutes was obtained as following: 4  30 seconds; 3  1
minute; 2  2.5 minutes; 2  5 minutes; and 4  10 minutes.
PMP PET Imaging
[11C]PMP was prepared in high radiochemical purity (>95%)
by N-[11C]methylation of piperidin-4-yl propionate using a
previously described method.44 Dynamic PET scanning was
performed for 70 minutes immediately following a bolus intra-
venous injection of 666MBq (18mCi) of [11C]PMP. The dose
contained <200lg cold PMP mass. Emission data were col-
lected in 16 sequential emission scans (the DTBZ protocol plus
an addition 10-minute frame).
DASB PET Imaging
The DASB PET studies were acquired as 17 sequential emission
scans (the DTBZ protocol plus 2 additional 10-minute frames)
in 35 subjects. Radiotracer was administered as a bolus
(666mBq of 18mCi 11CDASB containing <8lg of cold
DASB) plus constant infusion using 70% as a slow bolus over
30 seconds, followed by constant infusion of the remaining
30% over the 80-minute study duration.
Magnetic Resonance Imaging
All subjects underwent brain magnetic resonance imaging on a
3T Philips Achieva system (Philips, Best, the Netherlands) uti-
lizing an 8-channel head coil and the ISOVOX exam card pro-
tocol primarily designed to yield isotropic spatial resolution. A
standard T1-weighted series of a 3D inversion recovery-pre-
pared turbo field echo was performed in the sagittal plane using
repetition time/echo time/inversion time, 9.8/4.6/1,041 milli-
seconds; turbo factor, 200; single average; field of view, 240 
200  160mm; acquired matrix, 240  200. One hundred
sixty slices were reconstructed to 1mm isotropic resolution.
This sequence maximizes contrast among gray matter, white
matter, and cerebrospinal fluid and provides high-resolution
delineation of cortical and subcortical structures.
Data Analysis
Interactive Data Language image analysis software (Research
Systems, Boulder, CO) was used to manually trace volumes of
interest (VOIs) on magnetic resonance images to include the
thalamus, limbic cortex (hippocampus and amygdala), cerebellar
cortex, caudate nucleus, and putamen of each hemisphere. Total
FIGURE: Neocortical [11C]methylpiperidyl propionate positron
emission tomography signal in 2 subjects, 1 with (right) and
another without (left) symptoms of rapid eye movement sleep
behavior disorder (RBD). [Color figure can be viewed in the
online issue, which is available at www.annalsofneurology.org]
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neocortical VOIs were defined using semiautomated threshold
delineation of the cortical gray matter signal.
All image frames were spatially coregistered within subjects
with a rigid-body transformation to reduce the effects of subject
motion during the imaging session. These motion-corrected PET
frames were spatially coregistered to the T1-weighted magnetic
resonance using standard coregistration procedures in SPM8b
implemented in Matlab 2010b (Mathworks, Natick, MA). Time–
activity curves for each VOI were generated from the spatially
aligned PET frames. 11C-DASB SERT and 11C-DTBZ VMAT2
distribution volume ratio was then estimated by using the Logan
plot graphical analysis method,45 with the time–activity curves as
the input function and the inferior posterior cerebellum as refer-
ence tissue for 11C-DASB40,46 and the neocortex as reference tis-
sue for 11C-DTBZ.45,47,48 A noninvasive kinetic analysis of the
k3 hydrolysis rate (AChE activity) was performed using a direct
estimation of k3, without use of an arterial input function, based
on the shape of the tissue time–activity curve alone.49
Standard pooled variance t or Satterthwaite’s method of ap-
proximate t tests was used for group comparisons (SAS version
9.1; SAS institute, Cary, NC). Chi-square testing was used to
compare gender distribution between the 2 groups. Standard t
tests were used during a post hoc analysis to determine whether
relative differences in cholinergic denervation found between sub-
groups were confounded by potential mimics of oneiric behavior.
Results
Demographic and Clinical Variables
Twenty-seven subjects (33.8%) had RBD symptoms
based on MSQ responses. No significant differences
between groups were seen in mean age, duration of
motor disease, MoCA scores, H-Y scale, or UPDRS
motor experiences of daily living or motor examination
(Table 1). RBD symptoms were more frequent among
male than female patients with PD (p < 0.05). A non-
significant trend toward higher nonmotor aspects of
experiences of daily living scores was seen in the subjects
with RBD symptoms compared to those without (p ¼
0.128).
Neuropsychological test performance in the 2
patient groups is listed in Table 2. Subjects with RBD
symptoms showed significantly lower performance on the
verbal learning test compared to those without (t ¼
3.913, p ¼ 0.0002). No significant differences were seen
between groups in attention, visuospatial function, or
executive function cognitive domain z scores.
AChE and VMAT2 PET Measures
Table 3 lists the mean neocortical, limbic cortical, and
thalamic AChE hydrolysis rates and striatal VMAT2
binding levels in each patient group. Subjects reported to
have RBD symptoms (n ¼ 27) exhibited significantly
decreased AChE hydrolysis rates compared to subjects
without (n ¼ 53) in Neocortical (see Figure 1), thalamic,
and limbic cortical regions. In contrast, no significant
differences emerged between groups in striatal VMAT2
binding. Analysis of covariance was performed to evalu-
ate group differences in AChE rates while controlling for
the degree of nigrostriatal denervation. The addition of
TABLE 1: Demographic and Clinical Information in Patients with and without Symptoms of RBD
Characteristic PD Subjects with
RBD Symptoms,
n ¼ 27, Mean 6 SD
PD Subjects without
RBD Symptoms,
n ¼ 53, Mean 6 SD
Statistical Significance
Age 63.4 6 6.7 65.3 6 7.1 t ¼ 1.12, p ¼ 0.26
Gender F 2/M 25 F 18/ M 35 v2 ¼ 6.7, p ¼ 0.009
Duration of motor disease, yr 6.4 6 3.7 5.8 6 4.0 t ¼ 0.63, p ¼ 0.524
MoCA score 26.0 6 2.3 26.3 6 2.0 t ¼ 0.60, p ¼ 0.548
Revised MDS UPDRS
nonmotor aspects of
experiences of daily living
7.4 6 5.1 5.7 6 4.4 t ¼ 1.53, p ¼ 0.128
Revised MDS UPDRS motor
aspects of experiences of
daily living
8.9 6 6.7 8.1 6 5.7 t ¼ 0.58, p ¼ 0.562
Revised MDS UPDRS motor
examination score
27.6 6 10.9 25.1 6 11.2 t ¼ 0.93, p ¼ 0.35
Hoehn and Yahr score 2.3 6 0.44 2.3 6 0.49 t ¼ 0.28, p ¼ 0.97
F ¼ female; M ¼ male; MDS ¼ Movement Disorder Society; MoCA ¼ Montreal Cognitive Assessment; RBD ¼ rapid eye move-
ment sleep behavior disorder; UPDRS ¼ Unified Parkinson Disease Rating Scale.
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striatal DTBZ as a covariate did not change significant
AChE group effects for any of the PMP regions (neocor-
tex, F ¼ 13.2, p < .0001; thalamus, F ¼ 11.5, p <
.0001; and limbic cortex (F ¼ 6.5, p ¼ 0.002).
Subgroup Analysis of Cerebral SERT Binding
Analysis of raphe nucleus and striatal SERT binding in
the subset of patients who underwent [11C]DASB PET
imaging (n ¼ 35) failed to show significant differences
between groups with (n ¼ 11) or without (n ¼ 24)
symptoms of RBD (see Table 3).
Post Hoc Analysis
We performed a post hoc analysis using other question-
naire data aimed at assessing for symptoms of RLS and
PLMD that could be perceived as RBD mimics by sleep
partners (Table 4). Twelve of 80 subjects reported mild
or worse symptoms of RLS on the IRLS. There were no
significant differences seen in neocortical (RLS group:
0.0228 6 0.0023 vs non-RLS group: 0.0227 6 0.0030;
t ¼ 0.169, p ¼ 0.868), limbic cortical (0.0411 6
0.0052 vs 0.0412 6 0.0057; t ¼ 0.06, p ¼ 0.952), or
thalamic (0.0415 6 0.0042 vs 0.0413 6 0.0012; t ¼
0.127, p ¼ 0.899) AChE activity. No significant differen-
ces were seen between these groups in California Verbal
Learning Test (CVLT) performance (Z ¼ 0.205 6
0.986 vs 0.598 6 1.37; t ¼ 1.194, p ¼ 0.236). Using
the Parkinson’s Disease Sleep Scale, we compared the
quartile of subjects with the most severe RLS symptom
scores on questions 4 and 10 to the remainder of the
cohort and again found no significant differences in neo-
cortical (0.0232 6 0.0023 vs 0.0226 6 0.0024; t ¼
0.973, p ¼ 0.334), limbic cortical (0.041 6 0.005 vs
0.041 6 0.001; t ¼ 0.4473, p ¼ 0.656), or thalamic
TABLE 2: Cognitive Testing Performance for PD Subjects with and without RBD Symptoms






Verbal learning z score 0.857 6 1.013 0.038 6 0.945 t ¼ 3.913, p ¼ 0.0002a
Attention z score 0.013 6 1.586 0.091 6 1.916 t ¼ 0.181, p ¼ 0.857
Visuospatial function z score 0.222 6 1.494 0.211 6 1.086 t ¼ 0.036, p ¼ 0.971
Executive function z score 0.326 6 1.027 0.222 6 1.129 t ¼ 0.399, p ¼ 0.690
aStatistically significant.
TABLE 3: Mean 6 SD Neocortical, Limbic Cortical, and Thalamic AChE Hydrolysis Rates (k3; min21), and
Striatal VMAT2 DVR in Patients with and without Symptoms of RBD
PET Methods PD with RBD sx,
n ¼ 29




Neocortical AChE k3 0.0213 6 0.0018 0.0236 6 0.0022 t ¼ 4.55, p < 0.0001a
Limbic cortical AChE k3 0.0388 6 0.0029 0.0423 6 0.0058 tapprox ¼ 2.85, p ¼ 0.0056a
Thalamic AChE k3 0.0388 6 0.0025 0.0427 6 0.0042 tapprox ¼ 4.49, p < 0.0001a
Putamen DTBZ DVR 1.7793 6 0.2266 1.8206 6 0.2981 t ¼ 0.63, p ¼ 0.53
Caudate DTBZ DVR 1.9689 6 0.3216 2.0189 6 0.3911 t ¼ 0.57, p ¼ 0.57




t ¼ 0.28, p ¼ 0.77




t ¼ 0.35, p ¼ 0.72
Mean 6 SD raphe and striatal SERT DVR in the subset of patients who underwent [11C]DASB SERT positron emission
tomography imaging (n ¼ 35). Student t values are presented with levels of significance. Satterthwaite’s method of approximate
t tests (tapprox) was used for comparison of groups with unequal variances.
aStatistically significant.
AChE ¼ acetylcholinesterase; DASB ¼ benzonitrile; DTBZ ¼ [11C]dihydrotetrabenazine; DVR ¼ distribution volume ratio;
PD ¼ Parkinson disease; RBD ¼ rapid eye movement sleep behavior disorder; SD ¼ standard deviation; SERT ¼ serotonin
transporter; sx ¼ symptoms; PET ¼ positron emission tomography.
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(0.4101 6 0.0033 vs 0.0416 6 0.0044; t ¼ 0.4473, p
¼ 0.656) AChE activity. There were no differences in
CVLT performance as well (Z ¼ 0.403 6 1.23 vs
0.218 6 0.989; t ¼ 0.679, p ¼ 0.499).
Discussion
This imaging study of 80 nondemented PD subjects
indicates that RBD symptoms are associated preferen-
tially with degeneration of brain cholinergic systems in
PD. We found no association between the degree of
striatal dopaminergic denervation or the loss of striatal or
raphe nucleus serotoninergic terminals and a history of
RBD symptoms. The [11C]PMP AChE imaging method
assesses the integrity of the 2 major brain cholinergic
projection systems in the brain: neocortical and limbic
cortical [11C]PMP retention measures basal forebrain
corticipetal projection system integrity, whereas thalamic
[11C]PMP retention is an index of the integrity of the
pedunculopontine nucleus (PPN)–lateral dorsal tegmen-
tal nucleus (LDTN) projection system. The preferential
association of diminished central nervous system cholin-
ergic terminals with a history of RBD symptoms in these
subjects suggests that these cholinergic systems are impor-
tant in the pathophysiology of RBD in PD.
The risk of developing a neurodegenerative disease
among patients with idiopathic RBD is roughly between
40 and 65% at 10 years, with approximately half of these
patients developing PD.50 Previous studies have shown a
link between nigrostriatal dopaminergic denervation and
RBD in alpha-synucleinopathies.51,52 Although striatal
dopaminergic denervation may be associated with idio-
pathic RBD,52 Kim et al recently demonstrated that the
severity of nocturnal motor symptoms in idiopathic
RBD does not correlate with striatal dopaminergic termi-
nal density as measured by dopamine transporter imag-
ing.53 Nigrostriatal dopaminergic denervation is a near
universal hallmark of PD; however, only a subset of PD
patients develop RBD. Additional underlying factors are
therefore likely to play key roles in the pathogenesis of
RBD.
RBD is likely caused by neuronal degeneration or
dysfunction in brain regions that regulate suppression of
skeletal muscle tone during REM sleep. Members of this
complex circuit include the cholinergic PPN and LDTN,
the serotonergic raphe nucleus, and glutamatergic and
monoaminergic projections from the parabrachial–pre-
coeruleus regions and the locus coeruleus (LC).54 Our
results provide support for the concept that degeneration
or dysfunction in this region of the brainstem causes
RBD, in that diminished thalamic cholinergic innerva-
tion is consistent with PPN-LDTN degeneration. A
small case series has reported that acetylcholinesterase
inhibitors such as donepezil can ameliorate the symptoms
of RBD, consistent with the hypothesis that degeneration
within brainstem cholinergic nuclei may play a role in
the pathogenesis of RBD.55 A recent postmortem study
of patients with Lewy body diseases, however, found no
differences in the severity of PPN neuronal loss regardless
of RBD symptoms during life, suggesting that alpha syn-
uclein-mediated pathology in the pontine tegmentum
alone may not be sufficient to cause RBD in PD.56
The cholinergic magnocellular nuclei of the basal
forebrain complex is affected by Lewy body pathology in
Braak stage 3 and may account for some of the associa-
tion between RBD and cognitive impairment in PD.6
Although the basal forebrain complex plays an essential
role in cognition, it also has strong interconnections with
the brainstem nuclei regulating sleep and atonia during
REM. Recent experiments indicate that the basal fore-
brain complex may play an important role in the regula-
tion of arousal and sleep.57 This arousal projection sys-
tem of the basal forebrain complex is linked to the
pontine parabrachial–precoeruleus complex, suggesting
the existence of functionally important interactions
between these pontine nuclei and basal forebrain cholin-
ergic systems.57 What role the basal forebrain complex
may play in the pathogenesis of idiopathic RBD is cur-
rently unclear, although early neuronal dysfunction in
the cholinergic nucleus basalis of Meynert provides a
potential mechanism for the link between antecedent idi-
opathic RBD and the subsequent development of both
PD and dementia.58 Further in vivo studies of the integ-
rity of the basal forebrain complex, the PPN, and the LC
in idiopathic RBD may help to clarify this association.
Compared to nondemented subjects with PD,
patients with Alzheimer dementia (AD) have more pro-
nounced cholinergic denervation in limbic cortical
regions with less severe denervation seen in the
TABLE 4: Number of Subjects with and without
Symptoms of RBD on the MSQ Who Also Noted
Symptoms of Restless Leg Syndrome on Either the









Negative 39 (48.75%) 14 (17.5%)
Positive 16 (20%) 11 (13.75%)
IRLS ¼ International Restless Leg Scale; MSQ ¼ Mayo
Sleep Questionnaire; PDSS ¼ Parkinson’s Disease Sleep
Scale; RBD ¼ rapid eye movement sleep behavior disorder;
sx ¼ symptoms.
Kotagal et al: RBD and PD
April 2012 565
neocortex.8 Thalamic cholinergic denervation is not a
recognized feature of AD.59,60 Neocortical cholinergic de-
nervation is more severe and extensive in parkinsonian
dementia compared to AD.8 The degree of neocortical
cholinergic denervation seen in our cohort of PD subjects
with RBD symptoms is approximately intermediate
between the levels seen in parkinsonian dementia and
PD without dementia. We did not find significant differ-
ences in cognitive test performance between the groups
with and without RBD symptoms except for significantly
decreased performance on the verbal learning test in sub-
jects with symptoms of RBD. These findings are consist-
ent with a previous study by our group showing an asso-
ciation between hyposmia in PD, poor performance on
verbal learning testing, and neocortical and limbic corti-
cal cholinergic denervation.32 We propose that the pres-
ence of basal forebrain cholinergic dysfunction may rep-
resent a pathological mechanism contributing to the
development of dementia in patients who suffer from idi-
opathic RBD.
A limitation of our study is that the diagnosis of
RBD is based on questionnaire data and not confirmed
by polysomnography (PSG). Others have argued that the
diagnostic criteria for probable RBD can be fulfilled by
positive responses to questions listed on the MSQ sup-
plemented by affirmation of specific subquestions,
although the gold standard remains video PSG.61 The
proportion of subjects with RBD symptoms in our
cohort (33.8%) is within the range of previously pub-
lished estimates of RBD prevalence among patients with
PD (15–47%).62 However, bed partner-reported dream
enactment behavior in some cases conceivably could
reflect other common sleep phenomena in PD such as
periodic limb movements of sleep, restless leg syndrome,
or a manifestation of obstructive sleep apnea. Our post
hoc analysis suggests that presence of RLS/PLMD is not
associated with cholinergic denervation in our cohort.
The MSQ is a well-validated instrument and may yield
an increased sensitivity for detecting dream enactment
behavior compared to traditional PSG methods.17 The
relatively lower specificity (74%) of this questionnaire
relative to PSG-based diagnosis may also reflect the inter-
mittent presence of increased motor tone during REM
sleep, a finding that may not fully be captured by a sin-
gle overnight PSG. Determining the presence of REM
sleep without atonia on PSG is also not straightforward,
and such analyses may be confounded by potentially
poor inter-rater reliability.63 Furthermore, the false-posi-
tive rate of 26% seen in the MSQ validation study
decreased in the study population to 16% with an af-
firmative answer to subquestion 1d versus 17% with an
affirmative answer to subquestion 1e. We required
affirmative responses to both 1d and 1e to characterize
subjects as having RBD symptoms. It is also worth not-
ing that the MSQ validation study examined subjects
with AD, mild cognitive impairment, and tauopathies, as
well as subjects without any known neurodegenerative
disorders. With the higher prevalence of RBD in synu-
cleinopathies, we expect a higher specificity of the MSQ
in this population. Our study cohort represents a highly
enriched PD sample, as clinical diagnosis was confirmed
by nigrostriatal denervation on DTBZ PET imaging.
An additional point worth noting is that we are
interpreting decreased PMP retention as evidence of
cholinergic terminal degeneration, although we cannot
exclude the possibility of an alteration in AChE expres-
sion.64 The relationship between cholinergic denervation
and RBD symptoms in this study represents a strong cor-
relation, although it does not represent proof of causa-
tion. For example, subjects with RBD symptoms in our
cohort may have underlying brain changes consistent
with a predementia state, which conceivably could confer
a stronger association with symptoms of RBD than does
the cholinergic deficit that is associated with such a pre-
dementia state. We only studied SERT binding in a sub-
set of subjects, so we cannot exclude a small difference in
serotoninergic raphe neuron integrity between subjects
with and without RBD symptoms. The essentially equiv-
alent mean regional DASB binding values of these
groups indicate that if such a difference exists, it would
be rather small.
Despite these limitations, our data suggest that cho-
linergic projection systems in the pontine tegmentum
and basal forebrain complex could play a key role in the
pathogenesis of RBD in PD and may contribute to the
propensity to develop cognitive impairment found in
such patients. Differential cholinergic systems degenera-
tion in PD may reflect the existence of specific PD sub-
types. We speculate that cholinergic basal forebrain com-
plex dysfunction may have similar effects on sleep and
cognitive function in a number of related neurodegenera-
tive diseases. RBD and PD likely represent overlapping
neurodegenerative phenomena with common neuroana-
tomical substrates. Changes in the cholinergic nervous
systems within the brainstem and basal forebrain may
play a vital role in the pathophysiology of RBD and
hence have the potential to offer insight into the underly-
ing heterogeneity of a number of neurodegenerative dis-
eases. Longitudinal observational studies that follow risk
factors, clinical features, their association with in vivo pa-
thology involving various neuronal systems, and their
correlation with postmortem histopathologic findings are
necessary to further investigate the cause of RBD in PD
and in other neurodegenerative diseases.
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